Skip to main content
Caplight Logo









Bioherent

Bioherent

Private
MálagaHealthcare & Life Scienceshttps://bioherent.com/

Last Round

Early Funding

Jul 17, 2025

Total Funding Raised

$5.59M

Company Overview

Bioherent is a deep-tech company that develops next-generation in-vitro diagnostic (IVD) solutions using silicon photonics and proprietary surface chemistry for drug allergy testing.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotech Equipment, Biotechnology, Sensors

Business Model

B2B

Customer Profile

Usage-Based SaaS, Hardware Sales

AI Layer

Non-AI

Keywords

in-vitro diagnosticIVDdrug allergy testingpoint-of-care testingPOCTsilicon photonicsbiosensorsmedtechdiagnostic platformallergy diagnosticsmicrofluidicsnanotechnologyclinical diagnosticslab-on-a-chipdiagnostic cartridges

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Bioherent Comparables

Compare Bioherent with similar companies based on industry and business-model similarity.

Bioherent comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Allergios
83%
Eroica Dx
75%
Genalyte
69%

Bioherent Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingJul 17, 2025
SeedFeb 25, 2022

Key People

Founding team and executive leadership

Yara Aceta

Chief Executive Officer

Executive Team

Irene Dominguez Barragán

CFO

Executive Team

Bioherent Investors

Notable investors and investment history

Bioherent investors
InvestorRounds
CDTI InnvierteEarly Funding
Axon Partners GroupEarly Funding
Center for Technological Development and InnovationSeed
Bullnet CapitalEarly Funding, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 17, 2026

    Monthly visitors grew 2823% MoM, from 30 to 877.

  • Nov 7, 2025

    Monthly visitors grew 95% MoM.

Bioherent Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Bioherent Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Bioherent's valuation, stock price, and market status.

Firmographic Details

HeadquartersMálaga
Employee Range15
Year Founded2021
Last FundingJul 17, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?